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  2 
Aim: International collaboration is needed to enable large-scale pharmacogenomics studies in childhood 3 
asthma. Here, we describe the design of the Pharmacogenomics in Childhood Asthma [PiCA] consortium.  4 
Material & Methods: Investigators of each study participating in PiCA provided data on the study 5 
characteristics by answering an online questionnaire.  6 
Results: Twenty-one studies, including 14,227 children/young persons (58% male), from 12 different 7 
countries are currently enrolled in the PiCA consortium. Fifty-six percent of the patients are Caucasians. In 8 
total 7,619 were inhaled corticosteroid [ICS] users. Among patients from 13 studies with available data on 9 
asthma exacerbations, one third reported exacerbations despite ICS use. In the future pharmacogenomics 10 
studies within the consortium, the pharmacogenomics analyses will be performed separately in each 11 
center and the results will be meta-analyzed.  12 
Conclusions: PiCA is a valuable platform to perform pharmacogenetics studies within a multi-ethnic 13 
pediatric asthma population. 14 
 15 
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 17 
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Introduction  1 
Asthma is the most common chronic disease in childhood. Although it cannot be cured, effective 2 
treatments are available to decrease the symptoms, maintain lung function and prevent future 3 
exacerbations (1). Standard treatment regimens for persistent asthma include regular use of inhaled 4 
corticosteroids [ICS] combined with long-acting β2 agonists [LABA] and short-acting β2 agonists [SABA] as 5 
needed (2). There is heterogeneity in response to treatment; approximately 30-40% of the patients 6 
receiving ICS, do not show an improvement lung function and remain uncontrolled(3–6). Uncontrolled 7 
asthma is associated with low quality of life for patients and can be life threatening (7,8). Furthermore, 8 
unscheduled physician visits and hospital admissions due to exacerbations are responsible for almost half 9 
of the costs of asthma management (9,10). 10 
Poor adherence to medication, continuous environmental exposures, disease severity and misdiagnosis 11 
influence response to treatment in asthmatic patients. In addition, it has been shown that genetic 12 
variation contributes to the heterogeneity in treatment response (11). To date, a large number of 13 
candidate gene studies and several genome-wide association studies [GWAS] have been conducted to 14 
study the pharmacogenomics of childhood asthma (12,13). However, one of the main unmet needs for 15 
pediatric asthma management is the lack of clinically available biomarkers (for example pharmacogenetic 16 
markers) to guide asthma treatment. Genetic associations have been reported with three commonly used 17 
outcome measures (i.e. asthma exacerbations, asthma symptoms and lung function) (14,15). Different 18 
outcomes might reflect different aspects of asthma control and the heterogeneity in the outcome 19 
measures complicates the comparison of study results. In addition, most studies have been performed in 20 
relatively small study populations. There is a need for international collaboration in the field of 21 
pharmacogenomics of asthma to obtain large sample sizes of well-phenotyped asthmatic children to 22 
perform large scale meta-analysis to assess the clinical value of genetic markers for asthma management 23 
and identify markers that can guide asthma treatment. (16,17). There have been successful efforts to 24 
establish consensus on diagnosis and management of asthma (18,19). The Pharmacogenomics in 25 
Childhood Asthma [PiCA] consortium was initiated in December 2013 and brings together asthma studies 26 
that have genetic data and treatment outcome measures. The main goals of the PiCA consortium are to 27 
create a platform to identify new pharmacogenomic markers in asthma by conducting GWAS meta-28 
analyses. To replicate these new and also previously identified loci that are associated with treatment 29 
response,  and finally, to develop pharmacogenetics-guided (PG) algorithms to guide asthma therapy to 30 
improve symptoms and reduce/prevent future exacerbations. This is the first consortium that focuses on 31 




pharmacogenomics in childhood asthma. In this study, we describe the characteristics of the study 1 
populations currently included in the PiCA consortium, assess the outcome measures that can be used to 2 
study treatment response within the consortium and describe the design of the pharmacogenomics 3 
studies that will be performed within PiCA 4 
 5 
Methods 6 
PiCA consortium 7 
The PiCA consortium was established in December 2013 by the pharmacogenomics research group of 8 
Prof. dr. AH Maitland van der Zee (Utrecht University, The Netherlands) by expanding existing and new 9 
collaborations. Studies were identified from the literature, at conferences and by references of other 10 
PiCA collaborators. Studies were eligible to participate in the PiCA consortium if: 11 
 Data of asthmatic children or young persons were collected;  12 
 DNA samples were collected or could be collected; 13 
 Data were collected on asthma drug use; 14 
 Data were collected on treatment outcome.  15 
PiCA is a growing consortium and new studies can join the consortium if they meet the inclusion criteria 16 
(www.pica-consoortium.org).   17 
 18 
Data collection:  19 
 20 
An online questionnaire (created using www.surveymonkey.com) was sent to the investigators of each 21 
cohort to collect information about the patients and design of the studies.  22 
 23 
 24 
Characteristics of the studies and study populations  25 
Information was collected on the following characteristics of the studies: study design (i.e. asthma cohort, 26 
clinical trial and (high risk) birth cohort), country where the study was conducted and location of patient 27 
enrollment (type of health care centers: primary, secondary or tertiary care). Per study, the following data 28 
were collected on the study populations: the age range (in yrs.), number of male asthmatics, and the 29 
number of patients in distinct ethnic groups (i.e. Caucasians, African-Americans, Hispanics and Asians). In 30 
order to assess the potential of PiCA to perform pharmacogenomics studies, the numbers of patients with 31 




a reported use of asthma medication (ICS, SABA, LABA, Leukotriene modifiers [LTMs], Anti-IgE and Oral 1 
corticosteroids [OCS]) were collected per study. It was also ascertained whether data regarding 2 
environmental exposures and atopy were collected. The source for the DNA collection (i.e. blood, saliva) 3 
and availability of whole genome genotyping data was assessed.  4 
 5 
Outcome measures and treatment response  6 
The presence of information on exacerbations, asthma symptoms and lung function was assessed for 7 
each study. A severe exacerbation was considered as a short course (3-5 days) OCS use or a 8 
hospitalization/emergency room [ER] visit according to the American Thoracic Society/European 9 
Respiratory Society [ATS/ERS] 2009 statement (20). The presence of information on unscheduled General 10 
Practitioner [GP] visits or asthma-related absences from school was also assessed. The two outcomes 11 
have been used as indicators of exacerbations in several pharmacogenomics studies. For asthma 12 
symptoms, presence of information on validated asthma symptom questionnaires (asthma control 13 
questionnaire [ACQ] or Asthma Control Test [ACT]) was assessed within the studies. The comparability of 14 
the results of these two questionnaires has been shown previously (21). Patients with ACQ scores ≥0.75 15 
and ACT scores <20 were considered to have poor asthma control. In addition, availability of information 16 
on asthma symptoms based on guidelines (i.e. Global initiative for Asthma [GINA] and ATS/ERS) was also 17 
assessed. According to the availability of data in each study, the number of patients with exacerbations 18 
despite regular use of ICS was collected. For observational studies, the presence of any of these outcomes 19 
in the preceding six or twelve months was gathered. Asthma diagnosis is difficult in infants and pre-school 20 
children. Hence from birth cohorts within the PiCA consortium, we collected outcomes of children ≥ 6 21 
years of age with physician-diagnosed asthma. Cohen’s Kappa statistic was calculated per study, to show 22 
the overlap between patients experiencing exacerbations and asthma symptoms (22). This was calculated 23 
for those studies in which both outcomes were available. The analysis was performed in R (Package 24 
‘irr’)(23).  25 
Furthermore, since lung function measures are widely used as a response outcome in asthma, it was 26 
ascertained whether data regarding lung function measurements, especially changes in FEV1 from 27 
baseline over time (before and after treatment) and changes in FEV1 after SABA use were also collected 28 
within the studies included in the consortium.   29 
 30 
 31 




Results   1 
Baseline characteristics of the studies and patients 2 
Currently, 21 asthma studies from 12 different countries are enrolled in the PiCA consortium. PiCA 3 
includes 15 asthma cohorts, three birth cohorts, two high-risk birth cohorts (inclusion of infants based on 4 
allergic history of the mother) and one clinical trial (Table 1).  5 
In total, PiCA includes data of 14,227 asthmatic patients up to 25 years of age. In 17 studies (80%), 6 
asthma was based on physician-diagnosis and/or hospital records. For three studies asthma diagnosis was 7 
based on parental-reported asthma diagnosis. PACMAN included children with a regular use of asthma 8 
medication. Analysis of PiCA children showed that 58% are male. From almost all patients within PiCA 9 
(97%) information was available on ethnic background. The majority of the asthmatic patients in PiCA are 10 
Caucasian (56%), 12% are Asian, 22% are Hispanic, and 8% have an African/African-American background 11 
and the remaining (2%) has mixed/other ethnic backgrounds (Figure 1). In the PiCA consortium studies, 12 
data on medication use was collected based on parental/patient reports (17 studies), pharmacy records 13 
(nine studies), and physician’s prescriptions (five studies). Medication data was available for 12,736 14 
patients. Most of the patients in the studies were treated with ICS (n=7,619) and SABA (n=8,571). 15 
Furthermore, 2,050 patients received LABA, and 2,132 used LTRA. OCS as a maintenance medication was 16 
used in 568 patients (Figure 2). In line with clinical asthma guidelines, most patients were treated with a 17 
combination of different asthma medications. 18 
 19 
Outcome measures and treatment response  20 
Thirteen studies had information on exacerbations and approximately one third of the patients had 21 
severe exacerbations despite ICS treatment. In eleven studies (including 5,769 patients) data were 22 
available on OCS use as rescue medication despite ICS treatment. The prevalence of OCS use ranged 23 
between 7-67% in different studies, and in total 1,929 (33%) PiCA patients on ICS had received rescue 24 
OCS in the preceding 6-12 months of the study visit. Thirteen studies had data available on asthma-25 
related ER visits or hospitalizations despite ICS (n=6,095). The prevalence of ER visits/hospitalizations 26 
ranged between 7-67%. In total 1,806 (29%) patients reported asthma-related ER visits or 27 
hospitalizations. Data on asthma-related school absences despite ICS use were available for 2,587 28 
patients in six studies. Furthermore, data on unscheduled general practitioner (GP) visits were available 29 
for 1,479 patients in six studies (Figure 3). The total number of patients experiencing exacerbations in 30 
each study is shown in supplementary table 1.  31 




Validated scaled questionnaires to assess current asthma symptoms (ACQ and ACT) were used in five 1 
studies (DUCHA, ESTATE, PACMAN, PAGES and Singapore Cross Sectional Genetic Epidemiology Study) (in 2 
a total of 2,070 patients). In this population, 37% (n=766) of the patients had ACQ scores ≥ 0.75 or ACT 3 
scores <20 indicating poor asthma control. Furthermore, a modified version of the 1978 American 4 
Thoracic Society–Division of Lung Diseases Epidemiology Questionnaire (24) was used to assess current 5 
asthma control in GALA II and SAGE II in 1,725 patients; 41% had uncontrolled asthma symptoms based on 6 
this questionnaire. In addition to these scaled questionnaires, several other categorical measures of 7 
symptoms were used in studies. Modified GINA definition for long-term asthma control was used in 8 
BAMSE (n=226), with 34% of the patients having poor asthma symptoms. In the PIAMA study (n=110), 9 
43% of the patients using inhaled steroids had uncontrolled asthma at age eight. Guidelines of the Dutch 10 
Pediatric Society (NVK), which follow the GINA guidelines, were used to define uncontrolled asthma(25).  11 
Regarding lung function measurements, changes in FEV1 after bronchodilator were measured in seven 12 
studies and changes in FEV1 from baseline were measured in four studies.     13 
Information on asthma severity was available for 5,608 PiCA patients. The number of severe asthmatics 14 
according to ATS/ERS, GINA and British Thoracic Society/Scottish Intercollegiate Guidelines Network 15 
[BTS/SIGN] (step 4 or higher) guidelines was 838.  16 
 17 
Overlap between exacerbations and asthma symptoms:  18 
In three studies (GALA II, PACMAN and SAGE II), we could assess the overlap between exacerbations 19 
(defined by OCS use) and patients with asthma symptoms. In all three patient populations, there was only 20 
a slight to fair agreement between these two outcomes (kappa: 0.03-0.21); 46-72% of the patients with 21 
reported OCS use as a rescue medication also had uncontrolled asthma symptoms according to the 22 
asthma questionnaire. The overlap between patients with ER visits/hospitalizations in the past 6/12 23 
months and uncontrolled asthma symptoms in four studies (BAMSE, GALA II, PACMAN, and SAGE II) was 24 
also poor (Kappa: 0.03 to 0.22); 41-55% of the patients with ER visits/hospitalizations had uncontrolled 25 
asthma symptoms (supplementary table 2).  26 
 27 
Pharmacogenomic studies in PiCA: 28 
DNA samples have been collected in 20 studies, and for one study the DNA collection is still ongoing. The 29 
source of DNA per study is shown in table 1.  30 




A protocol written by the research center interested in a specific research question will be sent to the 1 
Principal investigators [PI] of the consortium for review. Next, the protocol will be sent to all PiCA studies. 2 
Centers that are willing to participate will perform the association analysis and the results will be sent to 3 
research center that initially initiated the research proposal. In case, individual study lack resources or 4 
expertise to perform the analyses, other PiCA collaborators will help to perform the analysis.   5 
GWAS in PiCA: 6 
Currently GWAS data is available for 13 studies (n= 6,743) (table 2). In addition, 1,967 DNA samples from 7 
5 studies will be genotyped; BAMSE (n=400), BREATHE (n=92), PAGES (n=514), GoShare (n=561) and 8 
SLOVENIA (n=400).  9 
In the discovery phase of the GWAS, genotyped samples will be imputed with the Michigan imputation 10 
server (Available at: https://imputationserver.sph.umich.edu). After imputation and quality check 11 
association analysis will be performed with EPACS (efficient and parallelizable association container 12 
toolbox. Available at: http://genome.sph.umich.edu/wiki/EPACTS). Principal component analysis and 13 
adjustment for gender and age will be performed when necessary. GWAS meta-analysis will be 14 
performed by METASOFT (26). In the replication phase, association analysis will be performed for the top 15 
hits identified in the discovery phase.  16 
Candidate gene approach in PiCA: 17 
Candidate gene studies will be conducted for newly identified SNPs from GWAS meta-analyses and for 18 
previously identified SNPs in GWAS of childhood asthma onset and pharmacogenomics of asthma and 19 
SNPs that might associate with treatment response based on biological pathways.  20 
Association analysis will be performed in the studies that have genotype or imputed data with high 21 
quality. The results of the association analysis will be meta-analyzed.  22 
23 





The PiCA consortium is a unique initiative that brings together data from 14,227 asthmatic 2 
children/young adults from 12 different countries worldwide. In genetic association studies, replication of 3 
the results across populations with different ethnic backgrounds is of high importance in order to support 4 
the findings of the pharmacogenomics analysis (27). The PiCA consortium is a novel platform to study the 5 
pharmacogenomics of uncontrolled childhood asthma despite asthma treatment.  6 
It is important to study pharmacogenomics of childhood asthma in addition to adult asthma, since asthma 7 
phenotypes differ between children and adults and findings in adult studies cannot be translated directly 8 
to the pediatric asthma population (28). For example, a genetic variant influencing FBXL7 expression has 9 
been found by the CAMP group to associate with improvement in asthma symptoms in response to ICS in 10 
two pediatric populations, but it failed to replicate in adults (13). Several GWAS of response to asthma 11 
medication have been published by the CAMP study group (29–31) and they can be found in the National 12 
Human Genome Research Institute [NHGRI] and the European Bioinformatics Institute [EMBL-EBI] GWAS 13 
catalog (32). In addition, variation in the ADRB2 gene has been associated with altered LABA response, 14 
but mainly in pediatric populations (33–36). Hence, it is important to study treatment response in 15 
asthmatic children. However, assessing treatment response in asthmatic children remains a challenging 16 
subject, as symptoms may vary over time. Different measures of uncontrolled asthma (i.e. exacerbations, 17 
symptoms, or lung function) might reflect distinct dimensions of the disease. It has been previously 18 
shown that demographic characteristics and biomarker profiles of children with severe exacerbations 19 
were different from children with persistent symptoms (15), and children without asthma symptoms can 20 
be prone to severe exacerbations(37). Furthermore, It has been shown that the definition of treatment 21 
response influences the genetic risk profile associated with drug response (38,29,39). Calculated Kappa 22 
values showed only minimal to moderate agreements between asthma symptoms and exacerbations. 23 
Since different dimensions of uncontrolled asthma include different patient populations and overlap only 24 
partly, distinct outcome measures need to be studied separately. An important strength of PiCA is the 25 
collection of well-defined asthma outcomes in > 14.000 individuals for future pharmacogenomics studies 26 
within the PiCA consortium, we will perform analyses using distinct measures of poor treatment response 27 
that reflect different dimensions of asthma.   28 
Within the PiCA consortium, we included study designs such as observational asthma cohorts and (high 29 
risk) birth cohorts. An observational study (cohort or case-control) is a common approach to assess 30 
pharmacogenomics and should not be undervalued. Observational studies can provide valuable evidence 31 




for clinically relevant pharmacogenomics markers. Once identified, the next step would be further 1 
replication and developing a prognostic biomarker test with additional replication for generalizability and 2 
investigating the functional biology to interrogate the mechanistic aspect of the replicated findings.  3 
 4 
Major strengths of the design of the PiCA consortium are inclusion of patients from mild to severe 5 
asthmatics with thoroughly investigated outcome and phenotype data (i.e. exacerbations and asthma 6 
symptoms), and the coverage of the broad spectrum of pediatric asthmatic medication users, which will 7 
make it possible to assess the value of pharmacogenetics for subgroups of patients. Study heterogeneity 8 
makes it possible to assess the generalizability of findings across multiple designs and/or multiple 9 
ethnicities. Sensitivity analyses can be used to assess for which group a certain marker might have the 10 
highest clinical value.  11 
In addition to large-scale pharmacogenomics studies, which are the main goal of this consortium, PiCA 12 
also has potential to study other factors influencing treatment outcomes, such as continued exposure to 13 
allergens or epigenomics. However, obtaining additional biological samples or data might be complicated 14 
for some PiCA studies, this might only be possible in part of the PiCA population. Several potential 15 
limitations of this consortium should be acknowledged. One of the limitations of  PiCA could be 16 
population stratification. However, this heterogeneity will help us to identify different genetic markers 17 
associated with the treatment response in patients with different ethnicities. Furthermore, it will help us 18 
to discover pharmacogenomics markers that are associated with the treatment response in asthmatics 19 
regardless of the ethnic background of the patients. In genome-wide association analyses, we will adjust 20 
the results of each cohort by principal components when necessary. In candidate gene studies, the 21 
analyses will be performed separately for each study and the results will be meta-analyzed. Furthermore, 22 
we will also perform sensitivity analysis by conducing separate analysis for patients with different ethnic 23 
backgrounds. The results of these analyses will be compared and in the presence of a significant 24 
difference, they will be reported.  Another limitation could be the wide age range of the patients included 25 
in PiCA, although this does reflect the general asthma population in clinical practice, infant onset asthma 26 
might be a different phenotype from asthma in teenagers (40). In addition, asthma diagnosis is 27 
complicated at a young age, and infants and pre-school children can suffer from symptoms (such as 28 
wheezing) similar to those caused by asthma. In PiCA we will only children include that were still suffering 29 
from asthma symptoms at ≥ 6 years of age. In the majority of the PiCA studies (17 out of 21), asthma was 30 
based on physician-diagnosis and/or hospital records. Although criteria for physician-diagnosis might 31 
differ between  countries, this difference reflects current clinical practice.  32 




This is the first large effort to unite childhood asthma studies with a common interest in 1 
pharmacogenetics. Various studies within PiCA have collected detailed information on asthmatic children 2 
and followed children prospectively, making PiCA a unique platform for collaboration and validation. 3 
Several other studies (Asthma Genetics in Hungary [AGH], EUROPA from the Netherlands, GoShare from 4 
the UK and the Canadian asthma cohort) are still in the stage of recruiting patients, data and genotyping 5 
DNA samples, and will participate in the future projects of the PiCA consortium. In other fields, such as in 6 
cardiovascular pharmacogenomics, large research consortia have delivered key discoveries (41–44). PiCA 7 
is a growing consortium and it provides the opportunity to study pharmacogenetics on a large scale, 8 
paving the way for precision medicine in asthma.  9 
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Table 1. PiCA characteristics: Study design and patient characteristics 1 
Study name (Ref in this 
article) 
Country Study design 
 











Medication DNA source  
ICS LABA SABA LTRA 
BAMSE[1]  Sweden General birth 
cohort 
Primary care 420 0-16 242 
(57.6) 
103 (11.0)  226 57 218 - Peripheral 
blood§ 
BREATHE[2]  UK Asthma cohort Primary and secondary 
care  
1570 3-22 1017 
(64) 




Canada Asthma cohort  Tertiary/quaternary 
referral center 
343 1-18 223 (65) - 343 54 343 79 Buccal cell and 
Saliva 
CAMP[3]  USA RCT Tertiary care 1041 5-12 621 (59) 95.6±18 311 - 418 - Peripheral 
blood§ 
COPSAC2000[4]  Denmark High risk birth 
cohort 
Written invitation 43 0-7  22(51) 94.4 (12.1) 43 * 43 * Peripheral 
blood§ 
COPSAC2010  Denmark General birth 
cohort 
Written invitation 90 0-5 52(57) 97.1 (12.1) 90 0 90 * Peripheral 
blood§ 
COPSACSevere* Denmark Asthma cohort Registry based 1173 0-25 791 (67) - * * * * Peripheral blood 
DUCHA Greece Asthma cohort Tertiary care 193 5-14 179 (92) 101.2 (12.8) 193 56 18 25 Peripheral blood 
ESTATe Netherlands Case-control Primary care  111 4-19 67 (60) - 110 42 111 2 Saliva§ 
followMAGICS[5] Germany/A
ustria   
Asthma cohort  Secondary and tertiary care 313 7-25 194 (62) - 150 104 107 27 Peripheral 
blood§ 
GALA II[6]# USA Case-control Secondary care, community 
and clinic-based 
recruitment 
2377 8-21 1288 
(54) 
90.8 (16.2) 1174 368 1900 610 Peripheral blood 
and Saliva§ 
Generation R#2[7]  Netherlands Population-based 
birth cohort 
Primary, secondary and 
tertiary care 
399 fetal-ongoing 249 
(62.4)  
100 (12.8) 200 50 280 10 Umbilical cord 
blood§ 




- Data not available, * Data collection ongoing, # patient inclusion ongoing. §Studies with GWAS data available. #2 Patient follow-up ongoing, numbers based on 1 
participation until April 1st, 2015, aged 9 years. BAMSE, Swedish abbreviation for Children, Allergy, Milieu, Stockholm, Epidemiology. CAMP, Childhood Asthma Management 2 
Program. COPSAC, The Copenhagen Prospective Study on Asthma in Childhood. DUCHA, . ESTATe, Effectiveness and Safety of Treatment with Asthma Therapy in children. 3 
GALA II, Genes-Environment and Admixture in Latino Americans. GOASC, Genetics of Asthma in Spanish Children. ICS, inhaled corticosteroids.  LABA, Long-acting Beta2 4 
agonist. LTRA, Leukotriene Receptor Antagonists. MAGICS, Multicenter Asthma Genetics in Childhood Study. PACMAN, Pharmacogenetics of Asthma Medication in Children: 5 
Medication with Anti-inflammatory effects. PAGES, Paediatric Asthma Gene Environment Study. PASS, Pharmacogenetics of adrenal suppression. PIAMA, The Prevention and 6 




GOASC[8]#  Spain Asthma cohort Secondary and tertiary care 125 2-18 76 (60) 94.6 (15.2) 125 78 14 107 Peripheral blood 
and Saliva 
PACMAN[9] Netherlands Asthma cohort Primary care 995 4-12 616 (61) - 844 229 819 87 Saliva§ 
PAGES[10]  UK Asthma cohort Primary, secondary and 
tertiary care 
701 2-18 519 (74) 94 (16) 648 347 696 286 Saliva 
PASS[11] UK 
 
Asthma cohort Tertiary care 525 5-18 307 (58) - 525 395 525 369 Peripheral blood 
and Saliva§ 
PIAMA[12]  Netherlands General birth 
cohort/ high risk 
birth cohort 
Primary care  428 8 254 
(59.3) 
105.4 (12.2) 208 28 210 5  
SAGE II[6]#  USA Case-control Secondary care, community 
and clinic-based 
recruitment 






Singapore Asthma cohort Tertiary care  1450 18-25 600 (41) 76.9 (12.8)  394* * * * * 
Slovenia[14] Slovenia Asthma cohort Tertiary care 350 5-19 162 (46) 89.9 (14.85) 193 * * 86 Peripheral blood 
Study of asthma in 
Puerto Rican children 
(HPR)[15] 




593 6-14 320 
(53.9) 
88.5 (16.5) 213 9 452 133 Peripheral 
blood§ 
Total:  21 studies 12 countries                                                                                                      14,227                                                                                                                   7,619           2,050            8,571              2,132                                                                                                                    




Table 2. Studies with GWAS 1 
Study Asthmatic patients, (n)  Genotyping chip  Genotyped SNPs* 
BAMSE 122 Illumina, Infinium 610 Quad Chip 582,892 
BREATHE 222 llumina Infinium Exome-24 
BeadChip 
172,660 
CAMP 124 illumina, HumanHap550v3 
Genotyping BeadChip 
486,706 












ESTATe 103 Illumina, Infinium CoreExome-24 
BeadChip 
538,267 
followMAGICS 311 Illumina Sentrix HumanHap300 
BeadChip 
309,560 
GALA II 1,900 Affymetrix, Axiom™  LAT1 array, 
World Array 4 
742,201 
HPR 593 Illumina HumanOmni2.5 
BeadChip 
1,300,000 
PACMAN 842 Illumina, Infinium CoreExome-24 
BeadChip 
518,648 
PASS 403 Illumina Omni Express 8v1 654,246 
SAGE II 817 Affymetrix, Axiom™ LAT1 array, 
World Array 4 
759,124 
Total  6,743    
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Fig 3.  Exacerbations despite regular use of ICS in the preceiding six months or year. A) Percentage of OCS users as a rescue medication in 11 PiCA studies. B) Percentage of 
patients with ER     visit/hospitalization in 13 PiCA studies. C) Percentage of patients with asthma-related school absences in 6 PiCA studies. D) Percentage of patients with 
unscheduled GP visits in 6 studies.  BCCAC; British  Columbia Childhood Asthma Cohort, Gen.R; Generation R, SCSGES; Singapore Cross Sectional Genetic Epidemiology Study. In 
PASS and BREATHE exacerbation data were available in the preceding 6 months. 





Supplementary Table 1. PICA characteristics: Treatment outcomes within the total 2 
population 3 
-  Data not available, * data not analyzed. 1 number of children with this outcome during past 6 months (Italic font) or past 12 months of cohort 4 
studies (bold font), currently in the birth cohort (underlined), or during the trial (standard font). ACQ-score ≥ 0.75 and ACT–score ≤ 19 is 5 
considered not well controlled asthma. #2 patient follow-up ongoing, numbers based on participation until April 2015, aged 9 years. N.a. not 6 
applicable at current stage. 7 













ACQ  N (%) ACT  N (%) 
BAMSE - 32 (7.6) 4 (1.0) - - - - 
PIAMA 2 (0.4) 3 (0.7) 2 (0.4) - 75 (17) - - 
PAGES 668 (95) - 289 (41) - -   - 64 (9) 
PACMAN1 60 (6) 61 (6.1) - - 61/953 (6.4) 406 (40) - 
followMAGICS - 12 (4) 6 (2) 75 (24) 108 (35) - - 
GALA II 745 (31) 1144 (48) 1195 (50) - - - - 
SAGE II 187 (18) 335 (33) 48 (4) - - - - 
GOASC 11 (8) 16 (12) 2 (1.6) - - - - 





38 (2.6)  120 (8) 34 (2.3) 170 (11) 309 (21) - 92 (6) 




232 (67) 214 (62) 67 (19) - 91 (26) - - 
PASS 309 (58) - 141 (26) - - - - 
CAMP 538 (51) 183 (17)  564 (54) 479 946) - - 
 HPR 229 (38) 279 (47) 98 (16) 355 (59) 467 (78) - - 
ESTATE 39 (35.1) 13 (11.7) - - 37 (33) - 32 (29) 





Supplementary table 2. Cohen’s Kappa values for different definitions of uncontrolled 2 
asthma 3 
4  Uncontrolled symptoms & OCS use  Uncontrolled symptoms & ER visits and/or hospitalizations  
Calculated values of Cohen’s Kappa 
HPR    
BREATHE    
GALA II 0.21 0.19 
PACMAN  0.03 0.03 
SAGE II 0.16 0.2 
BAMSE   0.22 
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